Delivering meaningful patient outcomes with advanced dendrimer technology Annual Report 2026 Contents ABN 20 078 532 180 Highlights 01 Chairman’s Report 02 Chief Executive Officer’s Report 04 Review of Operations 06 Directors’ Report (including Remuneration Report) 12...
2026 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Preliminary Final Report
- Becoming a substantial holder
- Ceasing to be a substantial holder
- Change in substantial holding
- Change of Director Interest Notice - R Basser
Later from Starpharma
- 2026 Appendix 4G and Corporate Governance Statement
- FY26 Key Financial Results and Annual Report
- S&P DJI Announces September 2026 Quarterly Rebalance
- Annual General Meeting 2026 Date
- Chair and Deputy Chair Appointments
